No Detail Found!

Exploring Metabolomic Drivers of Colorectal and Gastric Cancer: A Mendelian Randomisation Study

Author(s)
Yiming Wang Department of Clinical Medicine, Shandong Second Medical University,Weifang,China
Mi Jian Department of Gastrointestinal Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University,Yantai,China
Jinchen Hu Department of Gastrointestinal Surgery, The Affiliated Yantai Yuhuangding Hospital of Qingdao University,Yantai,China
Abstract
Objective: To evaluate the causal relationship between 1,400 metabolites and colorectal and gastric cancer. Study Design: Mendelian randomisation study. Place and Duration of the Study:The A liated Yantai Yuhuangding Hospital of Qingdao University, Yantai, China, from July to August 2024. Methodology: Metabolite genome-wide association study (GWAS) data and genetic data from the Canadian Longitudinal Study on Aging (CLSA) as well as the expensive FinnGen project, respectively, were sourced. Suitable instrumental variables were chosen based on their association with metabolites at a genome-wide signi cance level, thus ensuring a high degree of reliability in the causal inferences drawn. Inverse variance weighting (IVW) was used for initial analysis. Sensitivity analyses were conducted using MR Egger regression and weighted median methods to validate ndings and assess potential pleiotropy or bias. Results: Metabolites were included in the study of 8,299 individuals. Gastric cancer included 1,307 cases and 287,137 controls; while colorectal cancer included 6,509 cases and 287,137 controls. The research identi ed sixty-nine metabolites associated with varying degrees of risk enhancement or mitigation. For gastric cancer, a more focused discovery highlighted two metabolites with signi cant causal links associated with increased risk as well as a protective e ect. Sensitivity analyses con rmed the validity of these ndings. Conclusion: By elucidating speci c metabolites that exert direct causal e ects on colorectal and gastric cancer risk, the study marked a signi cant advancement in the understanding of the metabolic pathways involved in cancer development.
Publication Details
Page(s) 203-208
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 35, Issue: 2, Year: 2025

Request the full text from PASTIC

Keywords
colorectal cancer, Metabolites, Gastric cancer, genetic variants, Genome-Wide Association Studies, Causal inference, Mendelian randomisation
References
Sung H,Ferlay J,Siegel RL,Laversanne M,Soerjomataram I,Jemal A .2021 .GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 Countries. CA Cancer J Clin, 10(3) : 209-49.
Bray F,Ferlay J,Soerjomataram I,Siegel RL,Torre LA,Jemal A .2018 .GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 10(6) : 394-424.
Pavlova NN,Thompson CB .2015 .The emerging hallmarks of cancer metabolism. Cell Metab, 12(1) : 27-47.
Hanahan D. .2022 .Hallmarks of cancer: New dimensions. Cancer Discov, 21(1) : 2159-8290.
.2017 .m e s M V , K o r p e l a M A , S m i t h G D . M e n d e l i a n randomisation in cardiometabolic disease: Challenges in evaluating causality. Nat Rev Cardiol, 78(10) : 577-90.
Gupta V,Walia GK,Sachdeva MP .2016 .Mendelian randomisation: An approach for exploring causal relations in epidemiology. Public Health, 12 : 113-9.
Yarmolinsky J,Wade KH,Richmond RC,Langdon RJ,Bull CJ,Tilling KM .2018 .Causal inference in cancer epidemiology: What is the role of mendelian randomisation?. Cancer Epidemiol Biomarkers Prev, 17(9) : 1055-9965.
Inamura K. .2018 .Colorectal cancers: An update on their molecular pathology. Cancers, 10(1) : 26.
Li AM,Ye J .2020 .Reprogramming of serine, glycine and onecarbon metabolism in cancer. Biochim Biophys Acta Mol Basis Dis, 165841 : 165841.
Villar VH,Nguyen TL,Delcroix V,Teres S,Bouchecareilh M,Salin B .2017 .mTORC1 inhibition in cancer cells protects from glutaminolysis-mediated apoptosis during nutrient limitation. Nat Commun, 10 : 14124.
Peyraud F,Guegan JP,Bodet D,Cousin S,Bessede A,Italiano A .2022 .Targeting tryptophan catabolism in cancer immunotherapy era: Challenges and perspective. s Front Immunol, 807271 : 807271.
Nedeva C. .2021 .In ammation and cell death of the innate and adaptive immune system during sepsis. Biomolecules, 10(7) : 1011.
Calder PC .2017 .Omega-3 fatty acids and in ammatory processes: From molecules to ma. Biochem Soc Trans, 10(5) : 1105-15.
Larrauri AG,Presa N,Herrera AD,Ouro A,Trueba M,Munoz AG .2020 .Role of bioactive sphingolipids in physiology and pathology. Essays Biochem, 10(3) : 579-89.
Paul S,Lancaster GI,Meikle PJ .2019 .Plasmalogens: A potential therapeutic target for neurodegenerative and cardiometabolic disease. Prog Lipid Res, 74 : 186-95.
.2019 .. , 04 : .
Lee WJ .2019 .Vitamin c in human health and disease: E ects, mechanisms of action, and new guidance on intake. , : .
Ziberna L,Praznikar ZJ,Petelin A .2021 .Serum bilirubin levels in overweight and obese individuals: The importance of antiin ammatory and antioxidant responseAsn. tioxidants (Basel), 10(9) : 1352.
Dicks LMT .2024 .How important are fatty acids in human health and can they be used in treating diseases?. Gut Microbes, 2420765(1) : 2420765.
Sugimoto MA,Sousa LP,Pinho V,Perretti M,Teixeira MM .2016 .Resolution of in ammation: What controls its onsetF?ront. Immunol, 00160 : 160.
Wishart DS .2016 .Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov, 32(7) : 473-84.
Li Y,Lin Q,Lu X,Li W. .2021 .Post-diagnosis use of antioxidant vitamin supplements and breast cancer prognosis: A systematic review and meta-analysis. Clin Breast Cancer, 09(6) : 477-85.
Skriver C,Maltesen T,Dehlendor C,Skovlund CW,Schmidt M,Sorensen HT .2024 .Long-term aspirin use and cancer risk: A 20-year cohort study. J Natl Cancer Inst, 10(4) : 530-8.
Llido JP,Jayanti S,Tiribelli C .2023 .Gazzin S. Bilirubin and redox stress in age-related brain diseases. Antioxidants, 10(8) : 1525.
0

Citations

0

Downloads

76

Views